EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY 4.0

OncoTherad® (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette–Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway

João Carlos Cardoso Alonso, Bianca Ribeiro de Souza iD, Ianny Brum Reis iD, Gabriela Cardoso de Arruda Camargo, Gabriela de Oliveira, Maria Izabel de Barros Frazão Salmazo, Juliana Mattoso Gonçalves, José Ronaldo de Castro Roston, Paulo Henrique Ferreira Caria iD, André da Silva Santos, Leandro Luiz Lopes de Freitas, Athanase Billis und 2 weitere

International Journal of Molecular Sciences · 15.12.2023 · 24 (24) · 17535

DOI: 10.3390/ijms242417535 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.12.2023. Verfasst von João Carlos Cardoso Alonso und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIN), Universidade Estadual de Campinas (UNICAMP), Campinas 13083-865, São Paulo, Braz…. Hauptthemen laut MEDLINE: Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Immunotherapy. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: São Paulo Research Foundation, National Council for Scientific and Technological Development, São Paulo Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study assessed the safety and efficacy of OncoTherad® (MRB-CFI-1) nanoimmunotherapy for non-muscle invasive bladder cancer (NMIBC) patients unresponsive to Bacillus Calmette-Guérin (BCG) and explored its mechanisms of action in a bladder cancer microenvironment. A single-arm phase I/II study was conducted with 44 patients with NMIBC who were unresponsive to BCG treatment. Primary outcomes were pathological complete response (pCR) and relapse-free survival (RFS). Secondary outcomes comprised response duration and therapy safety. Patients’ mean age was 65 years; 59.1% of them were refractory, 31.8% relapsed, and 9.1% were intolerant to BCG. Moreover, the pCR rate after 24 months reached 72.7% (95% CI), whereas the mean RFS reached 21.4 months. Mean response duration in the pCR group was 14.3 months. No patient developed muscle-invasive or metastatic disease during treatment. Treatment-related adverse events occurred in 77.3% of patients, mostly grade 1–2 events. OncoTherad® activated the innate immune system through toll-like receptor 4, leading to increased interferon signaling. This activation played a crucial role in activating CX3CR1+ CD8 T cells, decreasing immune checkpoint molecules, and reversing immunosuppression in the bladder microenvironment. OncoTherad® has proved to be a safe and effective therapeutic option for patients with BCG-unresponsive NMIBC, besides showing likely advantages in tumor relapse prevention processes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsImmunotherapyAgedHumansAdjuvants, ImmunologicAdministration, IntravesicalBCG VaccineCX3C Chemokine Receptor 1Neoplasm InvasivenessNeoplasm Recurrence, LocalSignal TransductionToll-Like Receptor 4Tumor MicroenvironmentNanoparticle Drug Delivery SystemGlycoproteinsPhosphatesNanostructures

Stichwörter der Autor:innen

Oncotheradbacillus Calmette–Guerinbladder cancerimmunotherapynanotechnology

Substanzen

Adjuvants, ImmunologicBCG VaccineCX3C Chemokine Receptor 1Toll-Like Receptor 4Nanoparticle Drug Delivery SystemCX3CR1 protein, humanMRB-CFI-1GlycoproteinsPhosphates

Autor:innen und Institutionen

  • Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIN), Universidade Estadual de Campinas (UNICAMP), Campinas 13083-865, São Paulo, Brazil.
  • Paulínia Municipal Hospital, Paulínia 13140-000, São Paulo, Brazil.
  • Obstetrics & Gynecology Department, Ovarian Cancer Research Group University of British Columbia, Vancouver, BC V6Z 2K8, Canada.
  • Diagnosis and Surgery Department, Dentistry School, São Paulo State University (UNESP), Araraquara 14801-903, São Paulo, Brazil.
  • Pathology Department, Medical School, Universidade Estadual de Campinas (UNICAMP), Campinas 13083-888, São Paulo, Brazil.

ORCID-Profile: Bianca Ribeiro de Souza, Ianny Brum Reis, Paulo Henrique Ferreira Caria, Wagner José Fávaro

Förderung

  • São Paulo Research Foundation
  • National Council for Scientific and Technological Development
  • São Paulo Research Council
  • Brazilian National Council for Scientific and Technological Development

Zitieren

APA

Alonso, J. C. C., de Souza, B. R., Reis, I. B., de Arruda Camargo, G. C., de Oliveira, G., de Barros Frazão Salmazo, M. I., Gonçalves, J. M., de Castro Roston, J. R., Caria, P. H. F., da Silva Santos, A., de Freitas, L. L. L., Billis, A., Durán, N., & Fávaro, W. J. (2023). OncoTherad® (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette–Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway. International Journal of Molecular Sciences, 24(24), 17535. https://doi.org/10.3390/ijms242417535

Vancouver

Alonso JCC, de Souza BR, Reis IB, de Arruda Camargo GC, de Oliveira G, de Barros Frazão Salmazo MI, et al. OncoTherad® (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette–Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway. International Journal of Molecular Sciences. 2023;24(24):17535. doi:10.3390/ijms242417535

BibTeX
@article{Alonso2023,
  author = {Alonso, João Carlos Cardoso and de Souza, Bianca Ribeiro and Reis, Ianny Brum and de Arruda Camargo, Gabriela Cardoso and de Oliveira, Gabriela and de Barros Frazão Salmazo, Maria Izabel and Gonçalves, Juliana Mattoso and de Castro Roston, José Ronaldo and Caria, Paulo Henrique Ferreira and da Silva Santos, André and de Freitas, Leandro Luiz Lopes and Billis, Athanase and Durán, Nelson and Fávaro, Wagner José},
  title = {OncoTherad® (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette–Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {24},
  pages = {17535},
  doi = {10.3390/ijms242417535}
}
Kostenlos starten →